Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The noradrenergic agent reboxetine plus the antimuscarinic hyoscine butylbromide reduces sleep apnoea severity: a double‐blind, placebo‐controlled, randomised crossover trial
Richard Lim, Ludovico Messineo, Ronald R. Grunstein, et al.
The Journal of Physiology (2021) Vol. 599, Iss. 17, pp. 4183-4195
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea
Winfried Randerath, Johan Verbraecken, Christel A.L. de Raaff, et al.
European Respiratory Review (2021) Vol. 30, Iss. 162, pp. 210200-210200
Open Access | Times Cited: 132
Reboxetine Plus Oxybutynin for OSA Treatment
Elisa Perger, Luigi Taranto‐Montemurro, Débora Rosa, et al.
CHEST Journal (2021) Vol. 161, Iss. 1, pp. 237-247
Open Access | Times Cited: 56
The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial
Paula K. Schweitzer, Luigi Taranto‐Montemurro, Joseph Ojile, et al.
American Journal of Respiratory and Critical Care Medicine (2023) Vol. 208, Iss. 12, pp. 1316-1327
Open Access | Times Cited: 36
Novel avenues to approach non-CPAP therapy and implement comprehensive obstructive sleep apnoea care
Jean-Louis Pépin, Peter R. Eastwood, Danny J. Eckert
European Respiratory Journal (2021) Vol. 59, Iss. 6, pp. 2101788-2101788
Open Access | Times Cited: 43
Pharmacotherapy for obstructive sleep apnea - A systematic review and meta-analysis of randomized controlled trials
Yi‐Chieh Lee, Chun‐Ting Lu, Li‐Pang Chuang, et al.
Sleep Medicine Reviews (2023) Vol. 70, pp. 101809-101809
Open Access | Times Cited: 18
Efficacy of atomoxetine plus oxybutynin in the treatment of obstructive sleep apnea with moderate pharyngeal collapsibility
Paula K. Schweitzer, James Maynard, Paul Wylie, et al.
Sleep And Breathing (2022) Vol. 27, Iss. 2, pp. 495-503
Open Access | Times Cited: 26
Effects of atomoxetine plus a hypnotic on obstructive sleep apnea severity in patients with a moderately collapsible pharyngeal airway
Bruce Corser, Erica Eves, Jennifer Warren-McCormick, et al.
Journal of Clinical Sleep Medicine (2023) Vol. 19, Iss. 6, pp. 1035-1042
Open Access | Times Cited: 13
Atomoxetine and fesoterodine combination improves obstructive sleep apnoea severity in patients with milder upper airway collapsibility
Ludovico Messineo, Luigi Taranto‐Montemurro, N. Calianese, et al.
Respirology (2022) Vol. 27, Iss. 11, pp. 975-982
Open Access | Times Cited: 21
The combination of pimavanserin and atomoxetine reduces obstructive sleep apnea severity: a randomized crossover trial
Ludovico Messineo, M.H. Preuss, Ali Azarbarzin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
The norepinephrine reuptake inhibitor reboxetine alone reduces obstructive sleep apnea severity: a double-blind, placebo-controlled, randomized crossover trial
Thomas J. Altree, Atqiya Aishah, Kelly A. Loffler, et al.
Journal of Clinical Sleep Medicine (2022) Vol. 19, Iss. 1, pp. 85-96
Open Access | Times Cited: 16
Sleep apnea pathophysiology
Giovanni Andrisani, Giorgia Andrisani
Sleep And Breathing (2023) Vol. 27, Iss. 6, pp. 2111-2122
Open Access | Times Cited: 10
One Month Dosing of Atomoxetine plus Oxybutynin in Obstructive Sleep Apnea: A Randomized, Placebo-controlled Trial
Atqiya Aishah, Kelly A. Loffler, Barbara Toson, et al.
Annals of the American Thoracic Society (2022) Vol. 20, Iss. 4, pp. 584-595
Closed Access | Times Cited: 15
Topical Potassium Channel Blockage Improves Pharyngeal Collapsibility
A Osman, Sutapa Mukherjee, Thomas J. Altree, et al.
CHEST Journal (2022) Vol. 163, Iss. 4, pp. 953-965
Closed Access | Times Cited: 14
The combination of atomoxetine and dronabinol for the treatment of obstructive sleep apnea: a dose-escalating, open-label trial
Ludovico Messineo, Daniel Norman, Joseph Ojile
Journal of Clinical Sleep Medicine (2023) Vol. 19, Iss. 7, pp. 1183-1190
Open Access | Times Cited: 8
Stepwise Add-On and Endotype-informed Targeted Combination Therapy to Treat Obstructive Sleep Apnea: A Proof-of-Concept Study
Atqiya Aishah, B Tong, A Osman, et al.
Annals of the American Thoracic Society (2023) Vol. 20, Iss. 9, pp. 1316-1325
Closed Access | Times Cited: 8
Upper airway muscles: influence on obstructive sleep apnoea pathophysiology and pharmacological and technical treatment options
Elisa Perger, Luigi Taranto‐Montemurro
Current Opinion in Pulmonary Medicine (2021) Vol. 27, Iss. 6, pp. 505-513
Closed Access | Times Cited: 18
Combined noradrenergic plus antimuscarinic agents for obstructive sleep apnea - A systematic review and meta-analysis of randomized controlled trials
Shiqian Zha, Haizhen Yang, Yue Fang, et al.
Sleep Medicine Reviews (2022) Vol. 64, pp. 101649-101649
Open Access | Times Cited: 13
Turning Over a New Leaf—Pharmacologic Therapy in Obstructive Sleep Apnea
Jan Hedner, Ding Zou
Sleep Medicine Clinics (2022) Vol. 17, Iss. 3, pp. 453-469
Closed Access | Times Cited: 13
Relationship between Symptom Profiles and Endotypes among Patients with Obstructive Sleep Apnea: A Latent Class Analysis
Wan‐Ju Cheng, Eysteinn Finnsson, Eydís Arnardóttir, et al.
Annals of the American Thoracic Society (2023) Vol. 20, Iss. 9, pp. 1337-1344
Open Access | Times Cited: 7
Opioid Use Disorder, Sleep Deficiency, and Ventilatory Control: Bidirectional Mechanisms and Therapeutic Targets
Danny J. Eckert, H. Klar Yaggi
American Journal of Respiratory and Critical Care Medicine (2022) Vol. 206, Iss. 8, pp. 937-949
Open Access | Times Cited: 12
Sleep Deficiency and Opioid Use Disorder
Jennifer Langstengel, H. Klar Yaggi
Clinics in Chest Medicine (2022) Vol. 43, Iss. 2, pp. e1-e14
Open Access | Times Cited: 12
Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trial
Mathieu Berger, Geoffroy Solelhac, Nicola Andrea Marchi, et al.
SLEEP (2023) Vol. 46, Iss. 7
Closed Access | Times Cited: 6
New pharmacologic agents for obstructive sleep apnoea: what do we know and what can we expect?
Jan Hedner, Ding Zou
Current Opinion in Pulmonary Medicine (2022) Vol. 28, Iss. 6, pp. 522-528
Closed Access | Times Cited: 9
Targets for obstructive sleep apnea pharmacotherapy: principles, approaches, and emerging strategies
Richard L. Horner
Expert Opinion on Therapeutic Targets (2023) Vol. 27, Iss. 7, pp. 609-626
Open Access | Times Cited: 5
Obstructive sleep apnea phenotypes eligible for pharmacological treatment
Marie Bruyneel
Frontiers in Sleep (2023) Vol. 2
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top